An emerging concept in cancer therapeutics is the synthetic lethality-based treatment of tumors harboring BRCA1/2 mutations with poly(ADP-ribose) polymerase (PARP) inhibitors [54], [55]. This evidence concerns the gene BRCA1 and cancer.